HOME    SEARCH    ABOUT US    CONTACT US    HELP   
           
Rule: 37.114.204 Prev     Up     Next    
Rule Title: REPORTS AND REPORT DEADLINES
Add to My Favorites
Add to Favorites
Department: PUBLIC HEALTH AND HUMAN SERVICES
Chapter: COMMUNICABLE DISEASE CONTROL
Subchapter: Reporting Requirements
 
Latest version of the adopted rule presented in Administrative Rules of Montana (ARM):

Printer Friendly Version

37.114.204    REPORTS AND REPORT DEADLINES

(1) A local health officer must immediately report (within four hours) to the department by telephone the information cited in ARM 37.114.205(1) through (2) whenever a case of one of the following diseases or other condition of public health importance is suspected or confirmed:

(a) Anthrax;

(b) Botulism;

(c) Plague;

(d) Poliomyelitis, paralytic or nonparalytic;

(e) Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) disease;

(f) Smallpox;

(g) Tularemia; or

(h) Viral hemorrhagic fevers.

(2) A local health officer must transmit by telephone or secure electronic means to the department the information required by ARM 37.114.205(1) and (2) for each suspected or confirmed case of one of the following diseases, within the time limit noted for each:

(a) Information about a case of one of the following diseases should be submitted within 24 hours after it is received by the local health officer:

(i) an outbreak of a disease or condition specified in ARM 37.114.203;

(ii) any unusual incident of illness or death in a human or animal with potential human health implications;

(iii) Brucellosis;

(iv) Diphtheria;

(v) Gastroenteritis outbreak;

(vi) Influenza-associated hospitalization and mortality;

(vii) Measles;

(viii) Melioidosis;

(ix) Monkeypox; 

(x) Rabies in a human;

(xi) Rabies in an animal;

(xii) Rubella; and

(xiii) Syphilis.

(b) Information about a case of one of the following diseases must be submitted within seven calendar days after it is received by the local health officer:

(i) AIDS or HIV infection;

(ii) Anaplasmosis;

(iii) Arboviral diseases, neuroinvasive and non-neuroinvasive (California serogroup, Chikungunya, Eastern equine encephalitis, Powassan, Saint Louis encephalitis, West Nile virus, Western equine encephalitis, Zika virus infection);

(iv) Arsenic poisoning (≥ 70 µg/L total arsenic in urine; or ≥ 35 µg/L methylated plus inorganic arsenic in urine);

(v) Babesiosis;

(vi) Cadmium poisoning (≥ five µg/L total blood cadmium levels; or ≥ three µg/L total cadmium in urine);

(vii) Campylobacteriosis;

(viii) Candida auris (C. auris);

(ix) Chancroid;

(x) Chlamydial trachomatis infection;

(xi) Cholera;

(xii) Coccidioidomycosis;

(xiii) Colorado tick fever;

(xiv) Coronavirus Disease 2019 (COVID-19);

(xv) Cryptosporidiosis;

(xvi) Cyclosporiasis;

(xvii) Dengue virus infections;

(xviii) Giardiasis;

(xix) Gonorrhea;

(xx) Haemophilus influenzae, invasive disease;

(xxi) Hansen's disease (leprosy);

(xxii) Hantavirus pulmonary syndrome or infection;

(xxiii) Hemolytic uremic syndrome, post diarrheal;

(xxiv) Hepatitis A, acute;

(xxv) Hepatitis B, acute, chronic, perinatal;

(xxvi) Hepatitis C, acute, chronic;

(xxvii) Lead levels in a capillary blood specimen of ≥ 3.5 micrograms per deciliter(µg/dL) in a person less than 16 years of age;

(xxviii) Lead levels in a venous blood specimen at any level;

(xxix) Legionellosis;

(xxx) Leptospirosis;

(xxxi) Listeriosis;

(xxxii) Lyme disease;

(xxxiii) Malaria;

(xxxiv) Meningococcal disease (Neisseria meningitidis);

(xxxv) Mercury poisoning (≥ ten µg/L total mercury in urine; or ≥ ten µg elemental mercury/g in creatinine in urine; or ≥ ten µg/L elemental, organic, and inorganic blood mercury levels);

(xxxvi) Mumps;

(xxxvii) Pertussis;

(xxxviii) Psittacosis;

(xxxix) Q-fever (acute and chronic);

(xl) Salmonella Paratyphi infection;

(xli) Salmonella Typhi infection;

(xlii) Salmonellosis;

(xliii) Shigellosis;

(xliv) Spotted fever rickettsiosis;

(xlv) Streptococcus pneumoniae, invasive disease;

(xlvi) Streptococcal toxic shock syndrome (STSS);

(xlvii) Tetanus;

(xlviii) Tickborne relapsing fever;

(xlix) Toxic shock syndrome (nonstreptococcal) (TSS);

(l) Transmissible spongiform encephalopathies;

(li) Trichinellosis (trichinosis);

(lii) Tuberculosis (TB) including latent tuberculosis infection;

(liii) Varicella (chickenpox);

(liv) Vibrio cholera infection (cholera);

(lv) Vibriosis; and

(lvi) Yellow fever.

(3) Each week during which a laboratory-confirmed case of influenza is reported to the local health officer, the officer must transmit by secure electronic means to the department on Friday of that week the total number of the cases of influenza reported.

(4) For any animal exposure that may result in a risk of rabies transmission to a human by a species susceptible to rabies infection, the local health officer must report by secure electronic means to the department documentation of a rabies post-exposure prophylaxis recommendation or administration on a form provided by the department within seven calendar days of the recommendation or administration.

(5) A laboratory that performs testing associated with HIV infection must report:

(a) any test result or combination of test results that indicate HIV infection;

(b) all CD4 T-lymphocyte test results unless it is known that the test was performed in association with a disease other than HIV infection or HIV-related illness;

(c) HIV nucleic acid tests, RNA or DNA, irrespective of result;

(d) all test results for assays designed to assess HIV infection subtype and resistance to antiretroviral drugs, including nucleotide sequences, in a format designated by the department; and

(e) submit a specimen utilized for surveillance purposes only, to the department's public health laboratory upon request.

 

History: 50-1-202, 50-17-103, 50-18-105, MCA; IMP, 50-1-202, 50-17-103, 50-18-102, 50-18-106, MCA; NEW, 1987 MAR p. 2147, Eff. 11/28/87; AMD, 1994 MAR p. 1295, Eff. 5/13/94; AMD, 1995 MAR p. 1127, Eff. 6/30/95; AMD, 2000 MAR p. 2986, Eff. 9/22/00; TRANS, from DHES, 2002 MAR p. 913; AMD, 2006 MAR p. 2112, Eff. 9/8/06; AMD, 2013 MAR p. 967, Eff. 6/7/13; AMD, 2017 MAR p. 343, Eff. 3/25/17; AMD, 2019 MAR p. 1745, Eff. 1/1/20; AMD, 2022 MAR p. 1855, Eff. 9/24/22.


 

 
MAR Notices Effective From Effective To History Notes
37-971 9/24/2022 Current History: 50-1-202, 50-17-103, 50-18-105, MCA; IMP, 50-1-202, 50-17-103, 50-18-102, 50-18-106, MCA; NEW, 1987 MAR p. 2147, Eff. 11/28/87; AMD, 1994 MAR p. 1295, Eff. 5/13/94; AMD, 1995 MAR p. 1127, Eff. 6/30/95; AMD, 2000 MAR p. 2986, Eff. 9/22/00; TRANS, from DHES, 2002 MAR p. 913; AMD, 2006 MAR p. 2112, Eff. 9/8/06; AMD, 2013 MAR p. 967, Eff. 6/7/13; AMD, 2017 MAR p. 343, Eff. 3/25/17; AMD, 2019 MAR p. 1745, Eff. 1/1/20; AMD, 2022 MAR p. 1855, Eff. 9/24/22.
37-887 1/1/2020 9/24/2022 History: 50-1-202, 50-17-103, 50-18-105, MCA; IMP, 50-1-202, 50-17-103, 50-18-102, 50-18-106, MCA; NEW, 1987 MAR p. 2147, Eff. 11/28/87; AMD, 1994 MAR p. 1295, Eff. 5/13/94; AMD, 1995 MAR p. 1127, Eff. 6/30/95; AMD, 2000 MAR p. 2986, Eff. 9/22/00; TRANS, from DHES, 2002 MAR p. 913; AMD, 2006 MAR p. 2112, Eff. 9/8/06; AMD, 2013 MAR p. 967, Eff. 6/7/13; AMD, 2017 MAR p. 343, Eff. 3/25/17; AMD, 2019 MAR p. 1745, Eff. 1/1/20.
37-775 3/25/2017 1/1/2020 History: 50-1-202, 50-17-103, 50-18-105, MCA; IMP, 50-1-202, 50-17-103, 50-18-102, 50-18-106, MCA; NEW, 1987 MAR p. 2147, Eff. 11/28/87; AMD, 1994 MAR p. 1295, Eff. 5/13/94; AMD, 1995 MAR p. 1127, Eff. 6/30/95; AMD, 2000 MAR p. 2986, Eff. 9/22/00; TRANS, from DHES, 2002 MAR p. 913; AMD, 2006 MAR p. 2112, Eff. 9/8/06; AMD, 2013 MAR p. 967, Eff. 6/7/13; AMD, 2017 MAR p. 343, Eff. 3/25/17.
37-624 6/7/2013 3/25/2017 History: 50-1-202, 50-17-103, 50-18-105, MCA; IMP, 50-1-202, 50-17-103, 50-18-102, 50-18-106, MCA; NEW, 1987 MAR p. 2147, Eff. 11/28/87; AMD, 1994 MAR p. 1295, Eff. 5/13/94; AMD, 1995 MAR p. 1127, Eff. 6/30/95; AMD, 2000 MAR p. 2986, Eff. 9/22/00; TRANS, from DHES, 2002 MAR p. 913; AMD, 2006 MAR p. 2112, Eff. 9/8/06; AMD, 2013 MAR p. 967, Eff. 6/7/13.
9/8/2006 6/7/2013 History: 50-1-202, 50-17-103, 50-18-105, MCA; IMP, 50-1-202, 50-17-103, 50-18-102, 50-18-106, MCA; NEW, 1987 MAR p. 2147, Eff. 11/28/87; AMD, 1994 MAR p. 1295, Eff. 5/13/94; AMD, 1995 MAR p. 1127, Eff. 6/30/95; AMD, 2000 MAR p. 2986, Eff. 9/22/00; TRANS, from DHES, 2002 MAR p. 913; AMD, 2006 MAR p. 2112, Eff. 9/8/06.
Home  |   Search  |   About Us  |   Contact Us  |   Help  |   Disclaimer  |   Privacy & Security